Friday 6 November 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue: +1.33%
EPS: +418.2%
Free cash flow: −6.83%
Total debt: −42.2%

Quarter to June 2026, against a year earlier

72.79 0.13 +0.18%

Follow TECH

Alert me

Market cap: $11.4B
P/E: 62.2×
Fwd P/E: 54.2×
Dividend yield: 0.44%
F-score: 9/9
Altman Z: 15.50
Beneish M: −2.52
Dividend safety: 78/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bio-Techne Corp 10-Q filed Feb 6, 2025

Fiscal Q2 2025 · Period ended Dec 31, 2024 · Filed Feb 6, 2025 · accepted 4:30 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Nov 5, 2024: no material changes, the filing says